Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) delivers innovative medical device solutions addressing critical healthcare challenges in pain management, recovery, and digestive health. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and clinical advancements.
Access official press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnerships. Track Avanos Medical’s progress in advancing non-opioid therapies and life-sustaining nutritional support systems designed for hospital and home care settings.
Key updates include developments in cold compression technology, feeding tube innovations, and operational efficiency initiatives under the company’s ongoing transformation. All content is sourced directly from Avanos Medical and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined access to AVNS news that impacts clinical practice and investment decisions. Check regularly for updates on breakthrough medical technologies and their global healthcare applications.
Avanos Medical reported Q3 2021 financial results with net sales of $184 million, a decrease of less than 1% from the previous year. The company faced a net loss of $35 million, contrasting with a net income of $19 million from last year. Operating cash flow was $23 million, bolstered by $47 million in tax refunds. Despite challenges in acute pain due to elective procedure delays, operational metrics improved, including adjusted net income of $12 million. The gross margin stood at 49%, down from 52% last year, attributed to rising freight costs.
Avanos Medical, Inc. (NYSE: AVNS) is set to webcast its earnings call on Nov. 2, 2021, at 9 a.m. ET, discussing its third-quarter 2021 financial results. A news release will precede this call, detailing the company's performance before the market opens. The call features CEO Joe Woody and CFO Michael Greiner. Investors can access the live call via phone or a simultaneous webcast on the Avanos Medical website. A replay will be available later the same day.
Avanos Medical reported a strong second quarter of 2021 with net sales of $186 million, a 14% increase from last year, and net income of $38 million compared to a net loss in the previous year. The growth was driven by a recovery in elective procedures and the success of their Pain Management products, specifically COOLIEF and Game Ready therapies. Despite a temporary dip in gross margin to 46% due to increased transportation costs, the company remains optimistic about future improvement. A Deferred Prosecution Agreement with the DOJ has resolved past legal issues, enhancing compliance measures.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on August 3, 2021, at 9 a.m. ET, to discuss its second-quarter 2021 financial results and business highlights. A news release detailing these results will precede the call. Hosted by CEO Joe Woody and CFO Michael Greiner, interested parties can join by calling 877-240-5772 in the U.S. A replay will be available the same day at noon ET. Avanos Medical focuses on innovative healthcare solutions, operating in over 90 countries.
Avanos Medical, Inc. (NYSE: AVNS) has appointed Moji James as senior vice president & general counsel, effective immediately. With over 25 years of legal experience, James has previously served as chief legal officer at Tmunity Therapeutics and general counsel at Iroko Pharmaceuticals. Her extensive background in healthcare law and compliance is expected to enhance Avanos' strategic direction. CEO Joe Woody praised her qualifications, emphasizing the importance of her role in advancing the company's vision and addressing key healthcare needs.
Avanos Medical (NYSE: AVNS) announced an upcoming presentation by CEO Joe Woody at the Virtual 2021 Raymond James Human Health Innovation Conference on June 22 at 10:40 a.m. ET. A live webcast will be accessible in the Investors section of their website, with an archived version also available. Avanos is dedicated to providing innovative medical device solutions to enhance patient care and reduce opioid dependency.
Avanos Medical reported Q1 2021 results, with net sales of $181 million, unchanged year-over-year. The company experienced a net loss of $8 million, contrasting with a net income of $4 million last year. Adjusted net income rose to $11 million from $8 million. Gross margin decreased to 51% from 57%, primarily due to increased freight costs. The company expects 2021 net sales to increase by 2 to 4% and projects adjusted diluted earnings per share between $1.10 and $1.25. Free cash flow was an outflow of $9 million.
Avanos Medical will host a conference call on May 7, 2021, at 9 a.m. ET, to discuss its financial results for the first quarter of 2021. A news release detailing these results will be issued before market opening that day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Investors can join by dialing 877-240-5772 in the U.S. A replay will be available starting at noon ET on the same day. Avanos Medical focuses on innovative medical solutions, aiming to reduce opioid use and enhance patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) will have CEO Joe Woody present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at approximately 2 p.m. ET. A live webcast of the presentation can be accessed in the Investors section of Avanos Medical's website, where it will also be archived. Avanos Medical is dedicated to enhancing patient care and reducing opioid use through innovative medical devices.
Avanos Medical (NYSE: AVNS) announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 1 at approximately 3:50 p.m., ET. A live webcast of the presentation will be available on Avanos' Investors section and archived on their website.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
